Tissue engineering using human embryonic stem cells.

Stem Cell Center, Bruce Rappaport Faculty of Medicine, Technion - Israel, Haifa, Israel.
Methods in Enzymology (Impact Factor: 2.19). 02/2006; 420:303-15. DOI: 10.1016/S0076-6879(06)20014-4
Source: PubMed

ABSTRACT The possibility of using stem cells for tissue engineering has greatly encouraged scientists to design new platforms in the field of regenerative and reconstructive medicine. Stem cells have the ability to rejuvenate and repair damaged tissues and can be derived from both embryonic and adult sources. Among cell types suggested as a cell source for tissue engineering (TE), human embryonic stem cells (hESCs) are one of the most promising candidates. Isolated from the inner cell mass of preimplantation stage blastocysts, they possess the ability to differentiate into practically all adult cell types. In addition, their unlimited self-renewal capacity enables the generation of sufficient amount of cells for cell-based TE applications. Yet, several important challenges are to be addressed, such as the isolation of the desired cell type and gaining control over its differentiation and proliferation. Ultimately, combing scaffolding and bioactive stimuli, newly designed bioengineered constructs, could be assembled and applied to various clinical applications. Here we define the culture conditions for the derivation of connective tissue lineage progenitors, design strategies, and highlight the special considerations when using hESCs for TE applications.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: After tendon injury, the scar tissue that replaces the damaged tendon results in a substantial risk for reinjury. The goal of regenerative therapies is to restore normal structural architecture and biomechanical function to an injured tissue. Successful restoration processes for any tissue are thought to recapitulate those of development, in which there are spatial and temporal interactions between scaffold, growth factors, and cell populations.
    The Veterinary clinics of North America. Equine practice 05/2008; 24(1):191-201. DOI:10.1016/j.cveq.2007.11.002 · 1.05 Impact Factor
  • Source
    Organogenesis 10/2014; 6(4):245-51. DOI:10.4161/org.6.4.13284 · 2.60 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Human embryonic stem cells are pluripotent cells derived from the inner cell mass of the blastocyst. Once isolated in culture, they can produce stable cell lines with the capacity to provide differentiated cells from all three germ layers. This ability is the centre of an emerging field of research into applications ranging from tissue engineering and drug discovery to developmental biology and treatments for serious conditions such as Parkinson’s, diabetes and heart disease. An essential prerequisite for these developments is the production of banks of well-characterised and safety-tested cells for research and as seed stocks for therapeutic applications. This requires the cryopreservation of stem cells for long-term storage. Currently, conventional freezing and vitrification when applied to these cells has met with varying degrees of success. This has led to an emerging debate on the suitability of either method for cryopreservation of these cells. Such studies as have been undertaken have been empirical in nature, and to date, no methodological studies, such as those carried out on haematopoietic stem cells, have been published. This paper reviews the current debate on cryopreservation and places it in the context of stem cell banking for both research and therapy.
    Transfusion Medicine and Hemotherapy 01/2007; 34(4):293-304. DOI:10.1159/000104458 · 2.01 Impact Factor